Skip to main content
Fig. 3 | Journal of Experimental & Clinical Cancer Research

Fig. 3

From: Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells

Fig. 3

TME modifications induced by different treatments. Cell suspensions from tumors were analyzed by flow cytometry. A Analysis of CD39, MHC-class I (H2Kb), MHC-class II (IAb), CTLA-4, PD-L1 and TIM-3 expression on B16F10 cells (CD45neg). B expression of granzyme on CD8+ and CD4+ T cells, maturation of CD8+ and CD4+ T cells in central (CD44+CD62L+) and effector (CD44+CD62L-) memory cells and granzyme expression on effector memory CD8+ and CD4+ T cells. C IFN-γ expression on CD8+ and CD4+ T cells. D expression of CTLA-4, PD-1 and TIM-3 immune checkpoints on CD4+ and CD8+ T cells referred to CD3+. *p<0.05, **p<0.02, ***p<0.01

Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us